What question did this study set out to answer?

To compare the tumor response and adverse event profiles of imatinib mesylate against standard vinblastine and prednisolone therapy in dogs with cutaneous mast cell tumors.

February 7, 2022CellsOpen Access

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

View Full Paper

Ask AI

Bookmark

To compare the tumor response and adverse event profiles of imatinib mesylate against standard vinblastine and prednisolone therapy in dogs with cutaneous mast cell tumors.
Assessed 24 dogs with cutaneous mast cell tumors receiving either imatinib mesylate (n=13) or conventional vinblastine plus prednisolone (n=11).
Characterized tumors via histology, grading, and KIT immunostaining, while assessing tomographic response and adverse events via standard VCOG criteria.
The objective response rate was significantly higher in the imatinib group at 30.79% compared to 9.09% in the vinblastine and prednisolone group.
Adverse events were restricted entirely to grade 1 in the imatinib group, demonstrating significantly reduced toxicity compared to conventional therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative study demonstrates higher response rates and milder adverse events with imatinib in dogs with mast cell tumors, suggesting an effective alternative to standard chemotherapy.

Cite This Study

Macedo et al. (2022) studied this question.

synapsesocial.com/papers/6a8d0447eb815df85614e300 https://doi.org/10.3390/cells11030571

View Full Paper

Ask AI

Bookmark

Implication

Comparative study demonstrates higher response rates and milder adverse events with imatinib in dogs with mast cell tumors, suggesting an effective alternative to standard chemotherapy.

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Key Points

Discussion

Implication

Cite This Study

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider